Loading stock…

Medacta Group SA (MOVE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Medacta Group SA

MOVEMarket cap $2.73BPrice $137.0

Country🇨🇭Switzerland

SectorHealthcare

IndustryHealthcare Equipment

Designs and manufactures hip and knee implants used in minimally invasive joint replacement surgeries worldwide. Its patented ATTUNE-rivaling M-motion technology lets surgeons operate through smaller incisions, cutting patient recovery time significantly compared to traditional techniques.

In Bastion Portfolios?

52W Return-26%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+20%9

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+12%7

Rev CAGR (5y)+13%8

Earnings Forecast

EPS Growth Y+1-3%3

EPS Growth Y+2+17%8

EPS Growth Y+3+15%8

Quality

Margins

EBIT Margin15%6

Net Income Margin11%6

Free Cash Flow Margin-0%3

Debt

Net Debt/EBITDA1.65

Efficiency

ROE17%7

ROA8%8

Earnings Stability55

GEAR+AVERAGE50

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)233

P/E Ratio (Forward 3y)193

P/BV5.13

EV Multiples

EV/EBITDA Fwd134

EV/EBIT Fwd223

Yield

Free Cash Flow Yield-0.1%3

Dividend Yield0.5%2

Momentum

Short term

1 month return-7%4

3 month return-16%2

YTD return-27%2

Mid term

Price vs 52wHigh65%3

1 year return-24%2

Long term

3 year return+1%3

5 year return-16%3

Risk Shield

Price Risk

Beta0.85

Volatility27%8

Free Cash Flow

Free Cash Flow Margin-0%3

Free Cash Flow Yield-0.1%3

Quality

ROCE15%7

Earnings Stability55

Net Debt/EBITDA1.65

02Growth

Is it actually growing, and how fast?

MOVEMedacta Group

Revenue FY25$803M

GROWTH RATING↗

AVERAGE67 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+20%9

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-3%3

EPS growth, FY27E+17%8

EPS growth, FY28E+15%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 67% of companies worldwide.

Revenue grew 20%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

WATCH

Revenue is set to grow 12%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 20%/yr over the last 3 years; forecasts see it cooling to 12%/yr.

Earnings are set to grow in step with sales (EPS about 15%/yr vs revenue 12%/yr). One year dips: EPS falls 3% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOVEMedacta Group

Total return Current85.8%

Price return Current83.1%

MOMENTUM RATING↗

VERY WEAK10 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-16%2

YTD return-27%2

MID & LONG-TERM▾SCORE

% of 52-week high65%3

1-year return-24%2

3-year return+1%3

5-year return-16%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-7%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+1.3% over three years and -16% over five), behind 70% of the market.

It's down 24% over the past year, now 35% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-16%) and so far this year (-27%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Medacta Group SA. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MOVEMedacta Group

Revenue FY25$803M

GROWTH RATING↗

AVERAGE67 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+20%9

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+12%7

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-3%3

EPS growth, FY27E+17%8

EPS growth, FY28E+15%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 67% of companies worldwide.

Revenue grew 20%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

WATCH

Revenue is set to grow 12%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 20%/yr over the last 3 years; forecasts see it cooling to 12%/yr.

Earnings are set to grow in step with sales (EPS about 15%/yr vs revenue 12%/yr). One year dips: EPS falls 3% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOVEMedacta Group

Total return Current85.8%

Price return Current83.1%

MOMENTUM RATING↗

VERY WEAK10 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-16%2

YTD return-27%2

MID & LONG-TERM▾SCORE

% of 52-week high65%3

1-year return-24%2

3-year return+1%3

5-year return-16%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-7%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+1.3% over three years and -16% over five), behind 70% of the market.

It's down 24% over the past year, now 35% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-16%) and so far this year (-27%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Medacta Group SA. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community